쎌바이오텍 반기보고서 (2017.06)
1. 요약재무정보

가. 요약연결재무정보

구 분	제 23기 2분기	제 22기	제 21기

(2017년6월말)	(2016년12월말)	(2015년12월말)

[유동자산]	65,199,979,967	69,267,535,256	54,150,513,012

·현금및현금성자산	8,217,650,516	10,594,468,521	7,272,875,829

·매출채권및기타유동채권	11,315,730,338	10,792,304,471	9,311,574,554

·금융상품자산	41,624,756,949	45,198,950,000	34,606,184,587

·단기투자자산	-	-	-

·재고자산	2,560,772,449	2,052,900,092	2,521,478,081

·기타유동자산	1,481,069,715	628,912,172	438,399,961

[비유동자산]	24,810,831,766	21,261,696,865	20,817,336,026

·장기매출채권및기타비유동채권	474,866,052	342,479,173	264,874,621

·금융상품자산	5,000,000	5,000,000	505,000,000

·장기투자증권	285,889,014	266,592,405	287,043,173

·유형자산	22,599,741,962	19,524,253,609	18,780,486,861

·무형자산	1,241,166,078	939,269,664	843,148,796

·이연법인세자산	204,168,660	184,102,014	136,782,575

자 산 총 계	90,010,811,733	90,529,232,121	74,967,849,038

[유동부채]	7,348,677,605	6,360,902,280	6,163,135,072

[비유동부채]	20,952,000	15,476,000	47,462,020

부 채 총 계	7,369,629,605	6,376,378,280	6,210,597,092

[지배기업 소유주지분]	82,641,182,128	84,152,853,841	68,757,251,946

[자본금]	4,700,000,000	4,700,000,000	4,700,000,000

[자본잉여금]	12,759,754,094	12,759,754,094	12,759,754,094

[자본조정]	(12,921,092,595)	(5,260,426,445)	(5,260,426,445)

[기타포괄손익누계액]	51,437,361	33,453,542	48,368,033

[이익잉여금]	78,051,083,268	71,920,072,650	56,509,556,264

[비지배지분]	-	-	-

자 본 총 계	82,641,182,128	84,152,853,841	68,757,251,946

기 간	(2017.01.01~	(2016.01.01~	(2015.01.01~

2017.06.30)	2016.12.31)	2015.12.31)

매출액	31,932,989,343	58,275,830,849	49,504,515,603

영업이익	12,996,951,493	21,561,007,533	18,758,807,947

당기순이익	10,377,010,618	18,498,516,386	17,505,140,264

지배기업 소유주지분	10,377,010,618	18,483,601,895	17,505,140,264

비지배지분	-	-	-

주당순이익	1,368	2,396	2,268

연결에포함된회사수	3	3	3

나.요약별도재무정보

구 분	제 23기 2분기	제 22기	제 21기

(2017년6월말)	(2016년12월말)	(2015년12월말)

[유동자산]	65,172,526,699	68,130,327,104	53,860,925,500

·현금및현금성자산	6,413,188,652	10,048,170,009	6,822,021,385

·매출채권및기타유동채권	13,657,323,803	11,300,441,465	10,418,352,866

·금융상품자산	41,124,756,949	44,298,950,000	33,706,184,587

·단기투자자산	-	-	-

·재고자산	2,516,879,243	1,995,382,673	2,488,101,480

·기타유동자산	1,460,378,052	487,382,957	426,265,182

[비유동자산]	25,847,099,891	23,717,557,562	22,233,829,427

·장기매출채권및기타비유동채권	37,850,411	37,850,411	8,850,411

·금융상품자산	5,000,000	5,000,000	505,000,000

·장기투자증권	178,570,899	166,528,857	224,009,929

·종속기업투자주식	3,218,445,020	3,218,445,020	2,118,819,740

·유형자산	21,351,928,268	19,386,662,974	18,616,137,994

·무형자산	941,841,903	775,249,663	689,416,428

·이연법인세자산	113,463,390	127,820,637	71,594,925

자 산 총 계	91,019,626,590	91,847,884,666	76,094,754,927

[유동부채]	6,750,091,766	6,216,204,771	5,415,695,302

[비유동부채]	25,952,000	20,476,000	47,677,600

부 채 총 계	6,776,043,766	6,236,680,771	5,463,372,902

[자본금]	4,700,000,000	4,700,000,000	4,700,000,000

[자본잉여금]	12,759,754,094	12,759,754,094	12,759,754,094

[자본조정]	(12,921,092,595)	(5,260,426,445)	(5,260,426,445)

[기타포괄손익누계액]	1,124,429	(592,760)	(3,298,882)

[이익잉여금]	79,703,796,896	73,412,469,006	58,435,353,258

자 본 총 계	84,243,582,824	85,611,203,895	70,631,382,025

종속ㆍ관계ㆍ공동기업 투자주식의 평가방법	원가법	원가법	원가법

기 간	(2017.01.01~	(2016.01.01~	(2015.01.01~

2017.06.30)	2016.12.31)	2015.12.31)

매출액	30,852,551,165	56,495,596,508	49,024,773,708

영업이익	13,186,279,594	21,126,350,787	19,214,527,103

당기순이익	10,537,327,890	18,065,115,748	17,330,744,519

주당순이익	1,389	2,340	2,245